23andMe (NASDAQ:ME – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($1.02) EPS for the quarter, Zacks reports. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.
23andMe Stock Up 1.5 %
ME stock traded up $0.05 during trading on Tuesday, reaching $3.40. 138,534 shares of the company’s stock were exchanged, compared to its average volume of 192,537. The firm has a market cap of $88.81 million, a PE ratio of -0.13 and a beta of 1.14. 23andMe has a 1-year low of $2.65 and a 1-year high of $16.52. The company’s fifty day moving average price is $3.46 and its 200-day moving average price is $5.41.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 23andMe in a research note on Saturday, January 18th.
About 23andMe
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Recommended Stories
- Five stocks we like better than 23andMe
- How to Buy Cheap Stocks Step by Step
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What Investors Need to Know to Beat the Market
- What Does the Future Hold for Eli Lilly?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.
